open access publication

Preprint, 2024

Vertical Transmission of SARS-CoV-2 is Plausible During Pregnancy and Vaginal Delivery: A Prospective Cohort Study

Authorea, 10.22541/au.170666116.66260875/v1

Contributors

Milbak, Julie 0000-0002-4170-6558 [1] Holten, Victoria M F 0000-0002-5524-1712 [1] Axelsson, Paul Bryde 0000-0002-8403-0084 [1] Bendix, Jane Marie 0000-0003-3341-6689 [1] Aabakke, Anna J M 0000-0003-4754-506X [2] Nielsen, Lene Nørby [3] Friis, Martin Barfred [3] Løkkegaard, Ellen Christine Leth 0000-0003-4149-5663 [1] Jensen, Claus [1] Olsen, Tina Elisabeth 0000-0002-9471-472X [4] Rode, Line 0000-0002-9080-3389 [5] Clausen, Tine Dalsgaard 0000-0001-5585-2153 [1]

Affiliations

  1. [1] Nordsjællands Hospital
  2. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  3. [2] Holbæk Sygehus
  4. [NORA names: Region Zealand; Hospital; Denmark; Europe, EU; Nordic; OECD];
  5. [3] Herlev Hospital
  6. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  7. [4] Rigshospitalet
  8. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  9. [5] Rigshospitalet Glostrup
  10. [NORA names: Capital Region of Denmark; Hospital]

Abstract

Objective: To evaluate if SARS-CoV-2 is detectable in vaginal swabs and whether antibodies against SARS-CoV-2 are present in maternal and umbilical cord blood of pregnant women with COVID-19. Design: Prospective cohort study. Setting: Department of Obstetrics and Gynaecology, Copenhagen University Hospital – North Zealand, Denmark. Population: Pregnant women tested positive for SARS-CoV-2 in a pharyngeal swab between August 20th, 2020 and March 1st, 2021 who gave birth during the same period. Methods: Maternal blood sample and vaginal swabs were collected at inclusion. If included during pregnancy, these samples were repeated at delivery in addition to an umbilical cord blood sample. Swabs were analysed for SARS-CoV-2 and blood samples for SARS-CoV-2 total antibodies. Placental and neonatal swabs were performed on clinical indications. Main outcome measures: SARS-CoV-2 in vaginal swabs and SARS-CoV-2 total antibodies in maternal and umbilical cord blood. Results: We included 28 women, hereof 4 serious maternal or fetal outcomes including 1 neonatal death. Within the first eight days after a maternal positive pharyngeal swab, SARS-CoV-2 was detectable in two vaginal (2/28) and two placental swabs (2/4), whereas SARS-CoV-2 antibodies were detected in 1/13 women. After eight days, SARS-CoV-2 was not detectable in vaginal swabs and SARS-CoV-2 antibodies were observed in 19/21 of women. Antibodies in cord blood of seropositive mothers appeared after 16 days. Conclusion: Vertical transmission of SARS-CoV-2 seems plausible since SARS-CoV-2 is detectable in the vagina up to eight days after a positive pharyngeal swab at which time the neonate is not yet protected by antibodies.

Keywords

COVID-19, Copenhagen, Denmark, Department of Obstetrics and Gynaecology, Hereof, North Zealand, Obstetrics and Gynaecology, SARS-CoV-2, SARS-CoV-2 antibodies, SARS-CoV-2 total antibodies, Zealand, antibodies, birth, blood, blood of pregnant women, blood samples, clinical indications, cohort study, cord, cord blood, cord blood of pregnant women, cord blood samples, days, death, delivery, department, fetal outcomes, gynaecology, inclusion, indicators, maternal blood samples, measurements, mothers, neonatal death, neonatal swabs, neonates, outcome measures, outcomes, period, pharyngeal swabs, placental swabs, pregnancy, pregnant women, prospective cohort study, samples, seropositive mothers, study, swabs, total antibodies, transmission of SARS-CoV-2, umbilical cord blood, umbilical cord blood of pregnant women, umbilical cord blood samples, vagina, vaginal delivery, vaginal swabs, vaginitis, vertical transmission, vertical transmission of SARS-CoV-2, vertically, women

Data Provider: Digital Science